Sei Investments Co. increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 147.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 527,272 shares of the biotechnology company's stock after purchasing an additional 314,013 shares during the quarter. Sei Investments Co. owned approximately 0.22% of ADMA Biologics worth $9,043,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC purchased a new position in ADMA Biologics during the third quarter valued at $31,000. National Bank of Canada FI purchased a new position in ADMA Biologics during the 3rd quarter valued at about $35,000. GAMMA Investing LLC boosted its stake in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares in the last quarter. Vision Financial Markets LLC purchased a new stake in ADMA Biologics in the fourth quarter worth about $51,000. Finally, AlphaQuest LLC bought a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $84,000. 75.68% of the stock is currently owned by institutional investors.
ADMA Biologics Stock Down 3.9 %
ADMA stock traded down $0.78 during trading on Thursday, hitting $19.45. 2,261,932 shares of the stock traded hands, compared to its average volume of 3,523,887. The stock has a market cap of $4.60 billion, a price-to-earnings ratio of 69.46 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64. The firm's 50 day moving average is $17.41 and its two-hundred day moving average is $18.20.
Analyst Ratings Changes
Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.
Read Our Latest Stock Report on ADMA Biologics
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
